Compass Therapeutics' CTX-8371 Phase 1 Data Shows Durable Responses in Advanced Cancer; Cohort Expansions Underway
CMPX sits 19% above its 52-week low of $1.61.
Summary
Compass Therapeutics announced promising Phase 1 clinical data for its novel bispecific antibody CTX-8371 in patients with advanced malignancies who previously failed checkpoint inhibitors. The data, to be presented at ASCO, showed a 33% overall response rate at the two highest dose levels (2 of 6 evaluable patients) with durable responses, including 10.5+ months in TNBC and 7.5+ months in HL, alongside a favorable safety profile with no dose-limiting toxicities. This positive development for a pipeline asset follows recent mixed news regarding the company's lead drug, tovecimig. The company has initiated cohort expansions in NSCLC, TNBC, and HL, with additional data expected in Q4 2026.
At the time of this announcement, CMPX was trading at $1.91 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $347.6M. The 52-week trading range was $1.61 to $6.88. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.